Skip to main content

Table 2 Dose effect of chloroquine on blood pressure and other variables

From: Low dose chloroquine decreases insulin resistance in human metabolic syndrome but does not reduce carotid intima-media thickness

VariablePlacebo80 mg/week80 mg/day250 mg/dayP value
SBP (mmHg)121 ± 12121 ± 10123 ± 12123 ± 120.5607
DBP (mmHg)70 ± 771 ± 773 ± 873 ± 90.1107
MAP (mmHg)87 ± 888 ± 789 ± 990 ± 90.1944
Overnight MAP dip8.8 ± 4.29.5 ± 5.39.5 ± 8.89.6 ± 5.00.9878
Fasting glucose clamp5.77 ± 0.535.83 ± 0.525.83 ± 0.535.44 ± 0.650.0010*
Fasting glucose OGTT5.49 ± 0.575.77 ± 0.565.72 ± 0.625.66 ± 0.620.0805
OGTT AUC (mmol/L/h)16.93 ± 3.0517.65 ± 3.0017.87 ± 3.2217.26 ± 3.610.3585
Weight (kg)104 ± 18103 ± 18104 ± 19103 ± 190.6041
BMI35.9 ± 4.335.9 ± 4.235.9 ± 4.535.5 ± 4.60.5964
A1c (%)5.8 ± 0.4NDND5.8 ± 0.40.9493
Insulin (pmol/L)153 ± 94138 ± 62166 ± 107148 ± 800.4260
C peptide (nmol/L)1.16 ± 0.441.20 ± 0.381.26 ± 0.441.25 ± 0.360.5473
Glucagon (pg/mL)110 ± 41101 ± 26111 ± 54102 ± 500.3646
Leptin (μg/L)27.5 ± 11.627.2 ± 11.131.0 ± 16.427.2 ± 11.90.2134
NEFA (mmol/L)0.56 ± 0.150.55 ± 0.100.58 ± 0.190.55 ± 0.160.8776
TNFα (pg/mL)12.9 ± 1.813.0 ± 1.712.2 ± 1.912.4 ± 2.00.0890
Fibrinogen (μmol/L)8.44 ± 1.328.38 ± 1.478.14 ± 1.097.94 ± 1.440.3563
IL-6 (pg/mL)1.0 ± 1.61.4 ± 1.51.2 ± 1.60.96 ± 1.30.4282
Lp(a) (mg/dL)22.9 ± 17.520.9 ± 16.022.5 ± 17.222.8 ± 18.10.1454
CRP (mg/L)8.3 ± 10.87.9 ± 10.66.4 ± 7.27.5 ± 8.00.7455
Adiponectin (μg/mL)21.6 ± 8.1NDND20.6 ± 5.60.3503
Iron (μmol/L)12.3 ± 4.1NDND11.4 ± 5.50.5311
Iron Bind. Cap. (μmol/L)64.9 ± 8.7NDND65.8 ± 10.00.6385
Transferrin (mg/dL)300.3 ± 47.5NDND303.8 ± 48.50.6899
Transferrin Sat. (%)19.1 ± 6.4NDND17.2 ± 6.90.3413
Ferritin (pmol/L)170 ± 191NDND105 ± 880.0155*
  1. Data represent mean ± SD
  2. MAP mean arterial pressure, NEFA non-esterified fatty acids, ND not determined
  3. P values determined by repeated measures ANOVA except for A1c, adiponectin, and iron studies, where P value determined by paired t test